Personalized medicine and economic evaluation in oncology: All theory and no practice?

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 15, Issue 5, 2015, Pages 733-738

  Garattini, Livio ^a   Curto, Alessandro ^a   Freemantle, Nick ^b  

^a IRCCS Institute for Pharmacological Research Mario Negri   (Italy)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

cetuximab; economic evaluation; oncology; personalized medicine; targeted therapy; trastuzumab

Indexed keywords

CETUXIMAB; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

BREAST METASTASIS; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; HUMAN; MEDICAL DECISION MAKING; METASTATIC COLORECTAL CANCER; PATIENT IDENTIFICATION; PERSONALIZED MEDICINE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REIMBURSEMENT; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG INDUSTRY; ECONOMICS; GENETICS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PHARMACOGENETICS; PROCEDURES;

ANTINEOPLASTIC AGENTS; CETUXIMAB; DRUG DESIGN; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHARMACOGENETICS; PRECISION MEDICINE; TRASTUZUMAB;

EID: 84942835135     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2015.1078239     Document Type: Review

References (39)

1. Personalized medicine. Available from: www.futuremedicine.com/loi/pme
2. Journal of personalized medicine. Available from: www.mdpi.com/2075-4426/5/1
3. Pharmacogenomics and Personalized Medicine. Available from: www.dovepress. com/pharmacogenomics-and-personalized-medicine-journal
4. Current pharmacogenomics and personalized medicine. Available from: http://benthamscience.com/journal/index.php?journalID=cppm
5. Available from: www.epemed.org/online/www/content/ENG/index.htm
6. Available from: www.pharmgkb.org
7. Schleidgen S, Klingler C, Bertram T, et al. What is personalized medicine: sharpening a vague term based on a systematic literature review. BMC Med Ethics 2013;14:55
8. Redekop WK, Mladsi D. The faces of personalized medicine: a framework for understanding its meaning and scope. ViH 2013;16(6 Suppl):S4-9
9. Langreth R, Waldholz M. New era of personalized medicine: targeting drugs for each unique genetic profile. Oncologist 1999;4(5):426-7
10. Rogowski W, Payne K, Schnell-Inderst P, et al. Concepts of 'Personalization' in Personalized Medicine: Implications for Economic Evaluation. Pharmacoeconomics 2015;33(1):49-59
11. Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics 2010;28(11):1001-13
12. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/special-topics/general/general-content-000347.jsp&mid=WC0b01ac05800baeda
13. Mancinelli L, Cronin M, Sadée W. Pharmacogenomics: The Promise of Personalized Medicine. AAPS PharmSci 2000;2(1):Article 4
14. Jorgensen JT. New Era of Personalized Medicine: A 10-Year Anniversary. Oncologist 2009;14:557-8
15. Ginsburg GS, Konstance RP, Allsbrook JS, Schulman KA. Implications of pharmacogenomics for drug development and clinical practice. Arch Intern Med 2005;165(20):2331-6
16. Andre F, Mardis E, Salm M, et al. Prioritizing targets for precision cancer medicine. Ann Oncol 2014;25:2295-303
17. Haycox A, Pirmohamed M, McLeod C, et al. Through a Glass Darkly: Economics and Personalized Medicine. Pharmacoeconomics 2014;32:1055-61
18. EMA/446337/2011 9 June 2011
19. March R. Pharmacogenomics: the genomics of drug response. Yeast 2000;17(1):16-21
20. Collins FS, Varmus H. A new initiative on precision medicine. N Eng J Med 2015;372:793-5
21. Ginsburg GS, McCarthy J. Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol 2001;12(19):491-5
22. Damia G, Garattini S. The pharmacological point of view of resistance to therapy in tumors. Cancer Treat Rev 2014;40(8):909-16
23. Annemans L, Redekop K, Payne K. Current Methodological Issues in the Economic Assessment of Personalized Medicine. Value Health 2013;16:S20-6
24. Chalkidou K, Rawlins M. Pharmacogenetics and cost-effectiveness analysis: a two-way street. Drug Discov Today 2011;16(19-20):873-7
25. Payne K, Shabaruddin FH. Cost-effectiveness analysis in pharmacogenomics. Pharmacogenomics 2010;11(5):643-6
26. Antonanzas F, Juarez-Castello CA, Rodriguez-Ibeas R. Is personalized medicine a panacea for health management? Some thoughts on its desirability. Eur J Health Econ 2015;16:455-7
27. Leopold C, Vogler S, Habl C, et al. Personalised medicine as a challenge for public pricing and reimbursement authorities - A survey among 27 European countries on the example of trastuzumab. Health Policy 2013;113:313-22
28. Norum J, Risberg T, Olsen JA. A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann Oncol 2005;16:909-14
29. Lidgren M, Wilking N, Jönsson B, Rehnberg C. Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer. Acta Oncol 2008;47:1018-28
30. Poncet B, Bachelot T, Colin C, et al. Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis. Am J Clin Oncol 2008;31:363-8
31. Perez-Ellis C, Goncalves A, Jacquemier J, et al. Cost-Effectiveness Analysis of Trastuzumab (Herceptin) in HER2-Overexpressed Metastatic Breast Cancer. Am J Clin Oncol 2009;32:492-8
32. Matter-Walstra KW, Dedes KJ, Schwenkglenks M, et al. Trastuzumab beyond progression: a cost-utility analysis. Ann Oncol 2010;21:2161-8
33. Blank PR, Moch H, Szucs TD, et al. KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective. Clin Cancer Res 2011;17(19):6338-46
34. Asseburg C, Frank M, Köhne CH, et al. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. Clin Ther 2011;33(4):482-97
35. Vijayaraghavan A, Efrusy MB, Goke B, et al. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany. Int J Cancer 2012;131:438-45
36. Hoyle M, Peters J, Crathorne L, et al. Cost-Effectiveness of Cetuximab, Cetuximab Plus Irinotecan, and Panitumumab for Third and Further Lines of Treatment for KRAS Wild-Type Patients with Metastatic Colorectal Cancer. Value Health 2013;16:288-96
37. Garattini L, van de Vooren K, Curto A. Cost-effectiveness of trastuzumab in metastatic breast cancer: Mainly a matter of price in the EU? Health Policy 2015;119:212-16
38. Drummond M, Stoddart G, Torrance G. Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford; 1988
39. Garattini L, van de Vooren K, Zaniboni A. Ethics for end-of-life treatments: Metastatic colorectal cancer is one example. Health Policy 2013;109:97-103